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ABSTRACT
Background: Universal varicella vaccination
(UVV) for children introduced in Germany in
2004 resulted in a significant overall decline of
varicella-related hospitalizations (VRHs). We
investigated the incidence of specific types of
varicella-related complications (VRCs) in hos-
pitalized children and the impact of UVV on
VRCs during the first 7 years of UVV.
Methods: Children\17 years of age hospital-
ized with an ICD-10-based (International Classi-
fication of Diseases, 10th Revision) discharge
diagnosis of varicella were identified as VRH in
pediatric hospitals in Bavaria by annual stan-
dardized data queries of the hospital databases
(2005–2011). For each VRH, the hospitals repor-
ted basic demographic data, duration of hospital
stay, all diagnostic and procedural codes, and
outcome. VRCs were reported overall, per year,
and by immune status. Complication rates were
calculated as mean number per complication
category per hospital and per year; VRC trends
over time were assessed by linear regression.
Results: Between 78% (2005) and 61% (2011)
of Bavarian hospitals participated and reported
a total of 1263 VRHs. Specific VRCs were
reported in 954 (76%) children. Complication
rates per hospital and year decreased from 6.7
[95% confidence interval (CI): 5.1–8.3] in 2005
to 1.5 (95% CI: 0.8–2.3) in 2011, with the
strongest reduction of 90% in chil-
dren\ 5 years of age from 5.3 (95% CI: 4.0–6.6)
in 2005 to 0.5 (95% CI: 0.1–0.9) in 2011. Sig-
nificant decreases were observed for children
with upper respiratory tract (URT, by 97%),
lower respiratory tract (LRT, by 90%), skin (by
81%), gastrointestinal (by 78%), and neurologic
(by 65%) VRCs. Forty-eight children with VRCs
were immunocompromised; their annual rate
decreased by 87%.
Discussion: Corresponding to increasing vari-
cella vaccination coverage in the population,
the incidence of VRC decreased by 77% from
2005 to 2011, with the most substantial
decrease in the target group for UVV.
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Conclusion: Within 7 years, UVV in Germany
led to a decrease of about 77% of all types of
VRCs, with the highest reductions observed for
VRCs of the respiratory tract.
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Key Summary Points
Why Carry out This Study?
A decline in burden of pediatric varicella
was observed in all countries after
implementation of universal varicella
vaccination (UVV), including Germany.
However, impact of UVV on different
varicella-related complication (VRC)
categories in children hospitalized with
varicella is unknown in Germany to date.
What Was Learned from the Study?
Complication rates per hospital and year
in children\17 years declined by 77%
from 6.7 [95% conficence interval (CI):
5.1–8.3] cases per hospital in 2005 to 1.5
(95% CI 0.8–2.3) cases in 2011. Highest
reduction in cases was observed in
children below 5 years (by 90%), the
target group for UVV.
Gastrointestinal complications declined
by 78% from 2005 to 2011, neurologic
complications by 65%, skin complications
by 81%, upper respiratory tract
complications by 97% and lower
respiratory tract complications by 90%.
UVV can significantly reduce the burden
of varicella including societal costs.
BACKGROUND
The varicella zoster virus (VZV) is highly con-
tagious, usually resulting in a self-limiting,
mild, febrile, exanthematous childhood infec-
tion in healthy children. Especially immuno-
compromised children are at risk of severe
disease, but even in previously healthy children
infections may result in varicella-related hospi-
talizations (VRH) due to potentially severe
varicella-related complications (VRCs) [1–3]. In
a German study on varicella-related complica-
tions in the pre-vaccination era, neurologic
(25.4%), skin-related (23.2%), and gastroin-
testinal (15.0%) complications were most fre-
quently reported among immunocompetent
children\17 years, whereas in immunocom-
promised children lower respiratory tract (LRT,
37.5%), hematologic (31.3%), and gastroin-
testinal (25.0%) complications were most fre-
quently observed [1]. The incidences of VRH [4]
and of the different categories of VRCs, how-
ever, vary widely among studies and countries,
probably reflecting differences in region, vari-
cella vaccination coverage, population struc-
tures, and public health systems [1, 5, 6].
In Germany, varicella incidence in the
community was estimated as 930 per 100,000
inhabitants during the pre-vaccination era [7]
and the burden of VRH as 14.1 per 100,000
children\16 years of age [1] with an average of
five varicella-related fatalities per year [8].
Universal varicella vaccination (UVV) was
implemented in Germany for all children aged
11–14 months with a one-dose schedule in 2004
[9] and with a second dose at 15–23 months in
2009 [10]. Monovalent (V) and since 2006
tetravalent measles-mumps-rubella-varicella
(MMRV) vaccines are both available in Ger-
many. UVV was well accepted, with one-dose
vaccination coverage of 43% for chil-
dren\ 2 years of age born in 2004 to 87% in
children born in 2009 and resulted in a strong
decline of pediatric VRH overall [11].
In Bavaria, the second largest German Fed-
eral State, varicella vaccinations and their
impact were studied in the frame of the
‘Bavarian Varicella-Surveillance Project’
[12–18]. Similarly to other regions in Germany
until 2011, the coverage for first-dose varicella
vaccination in children aged 18–36 months
increased in the two observed Bavarian regions
to 69% and 83%, respectively [12–14]. Corre-
sponding to the observed increase in coverage,
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the estimated incidence of pediatric VRH of
13.3 and 16.8 per 100,000 children\17 years
of age in Bavarian hospitals in 2005 and 2006
continuously decreased in the following years
to 4.8 in 2011 [16].
Thus far, only limited data are available from
Germany and other countries on the magnitude
of UVV’s impact on different types of VRC in
children [19] and are mostly restricted to
specific complications, such as the decrease of
neurologic VRC published previously [16] by
our group. In the current article, we describe all
types of VRCs observed in children with VRH
within the ‘Bavarian Varicella Surveillance Pro-
ject’ and compare their decrease during the first
7 years of UVV.
METHODS
As part of the ‘Bavarian Varicella Surveillance
Project,’ all 37 pediatric hospital wards in
Bavaria, covering an annual pediatric popula-
tion of about 2 million children, were invited to
participate [16]. From 2005 to 2011, participat-
ing hospitals provided each year’s standardized,
anonymized data on all children with a vari-
cella-related ICD-10 (International Classifica-
tion of Diseases, 10th Revision) code.
VRHs were identified by using a pre-specified
algorithm with the following inclusion criteria:
children\17 years of age at admission; at least
one varicella-related ICD-10 code (B01.0–B01.9)
as the main or any secondary diagnosis at dis-
charge; stationary hospitalization for at least
1 day within the observation period from 1
January 2005 to 31 December 2011.
The hospitals reported basic demographic
data, month and year of hospital admission,
duration of hospital stay, all ICD-10 codes
(primary and secondary), and all procedural
codes (OPS). For each VRH, documented ICD-10
discharge codes indicating VRC were classified
using pre-specified diagnosis-related categories
of complications [1]: neurologic [16], gastroin-
testinal, skin, reactive arthritis, lower/upper
respiratory tract (LRT/URT), hematologic, sys-
temic bacterial, coagulation complication and
related sequelae, and other complications.
Codes indicating underlying chronic conditions
were allocated to previously described cate-
gories [16]. Immunocompromised children
were identified by ICD-10 codes indicating
malignancies or potentially relevant neoplasms
(C00-C97, D37-D48), immunodeficiency disor-
ders (D80-D89) and HIV/AIDS (B20-B24, Z21),
chronic juvenile arthritis (M08), nephrotic
syndrome (N04), or a code indicating a trans-
planted organ or tissue (Z94). For further details
on the study setting and data collection, see
Streng et al. [16, 18].
Ethical Considerations and Data
Protection
Approval was obtained from the Bavarian Data
Protection Office (Munich) and the Ethics
Committees of the Medical Faculties at the
University Hospitals in Munich and Wu¨rzburg.
The participating hospitals reported only
anonymized data.
Statistical Analysis
Data were collected from all hospitals using
Microsoft Excel tables and were analyzed with
SPSS version 25.0 (SPSS Inc., Chicago, IL).
Results of descriptive analyses were reported as
absolute numbers with percentages or as med-
ian values with interquartile range (IQR). Data
were compared using Pearson’s Chi2 test or
Fisher’s exact test for categorical data and the
Mann-Whitney U test for continuous data.
Complication rates per age group and per
complication category were calculated as mean
number of patients per hospital per year to
account for the different numbers of partici-
pating hospitals per year. The number of
patients per age group or per category was
divided by the number of participating hospi-
tals in the respective year (between 22 and 29
hospitals per year participated in the study; for
further details refer to Supplementary Table 1).
Explorative univariate linear regression analyses
were employed to assess VRC trends over time.
Mean number of VRCs per hospital per year was
entered as dependent variable and year of hos-
pitalization as independent variable. Analyses
were stratified by age group and by type of
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complication. Significance level was defined as
p\0.05 (two sided).
RESULTS
Characteristics of Patients with Varicella-
Related Hospitalizations (VRH)
From 2005 to 2011, 22–29 hospitals per year
(61–78% of all Bavarian pediatric hospitals,
representing about 80–87% of pediatric hospital
beds) participated in the study. Overall, 1263
children with VRH were reported (Table 1;
54.6% male patients; median age 3 years, IQR
1.0–5.0). Children\ 5 years of age represented
the largest group of VRH (67.8%), whereas only
few children were aged 10–16 years (6.0%).
Mean duration of hospital stay was 3 days (IQR:
2.0–6.0). An underlying chronic medical con-
dition was reported in 270 patients (21.4%);
most common were malignancies/hematologic
disorders/disorders of the immune system
(8.9%), and neurologic disorders (3.8%). Of all
1263 children with VRH, 5 (0.4%) showed par-
ticularly severe disease requiring treatment in a
pediatric intensive care unit (PICU), and 2
patients with fatal outcome were reported, of
which 1 was treated at a PICU (Supplementary
Table 2).
Characteristics of Patients with Specific
Varicella-Related Complications (VRCs)
Specific complications in varicella patients
(VRCs) were reported in 954 of 1263 hospital-
ized children (75.5%; Table 1); of these 518
(54.3%) were male. Demographic characteristics
of children with VRCs were comparable to the
309 (24.5%) children without specific VRCs.
Children aged \ 5 years made up the largest
group in patients either with or without a
specific VRC (69.3% vs. 63.1%, p = 0.114),
whereas the number of children aged between
10 and 16 years was lowest for both categories
(5.6% of patients with VRC vs. 7.4% of patients
without VRC). Interestingly, the proportion of
children with an underlying medical condition
was significantly lower in children with VRC
than in children without VRC (17.7% vs. 32.7%,
p\0.001), mainly because of a higher propor-
tion of children with malignancies/disorders of
the immune system in the group without VRC.
Median duration of hospital stay was longer in
children with VRC than in those without VRC
(4 days vs. 2 days; p\0.001). The main reason
for hospital admission in children with VRC
was the varicella infection (92.7% with a main
diagnostic ICD10 code for varicella,
B01.0–B01.9) compared with 64.1% (p\ 0.001)
in children without VRC.
Types of Varicella-Related Complications
(VRCs)
The most frequent specific VRCs were gastroin-
testinal complications in 339 (26.8%) of the
1263 varicella patients (Table 2), including
mainly patients with dehydration (18.0% of
1263) and enteritis/gastroenteritis (11.1%).
Neurologic complications were reported in 228
(18.1%) children; most frequent were febrile
convulsion (6.6%), encephalitis/meningitis
(5.3%), syncope (2.4%), and cerebral convul-
sions (2.3%). A varicella-related skin complica-
tion occurred in 178 (14.1%) children; most
frequent were dermatitis/eczema (5.1%), skin
and soft tissue infections (2.9%), and skin
abscesses (2.8%). In 21 of 217 (9.7%) children
with skin complications, secondary bacterial
skin infections were reported (Staphylococcus sp.
in 11 and Streptococcus sp. in 10 children).
Complications related to the upper respiratory
tract (URT) including the ears/nose/throat and
eyes affected 190 children (15.0%). The lower
respiratory tract (LRT) was affected in 160
(12.7%) children; 6.2% had pneumonia, 5.1%
bronchitis, 1.8% respiratory failure, and 1.7%
pleural effusion/pyothorax. Reported co-infect-
ing bacterial pathogens in children with LRT
were Streptococcus spec. (6 children), Mycoplasma
pneumoniae (3), Staphylococcus spec. (1), Hae-
mophilus influenzae (1), and Klebsiella pneumo-
niae (1). Reported co-infecting respiratory
viruses were respiratory syncytial virus (RSV) (9)
and influenza virus (1). In 26 (2.1%) children a
confirmed or suspected invasive bacterial
infection was reported: 18 (1.4%) had sepsis, 8
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Table 1 Characteristics of 1263 children with varicella-related hospitalization (VRH), with and without speciﬁc varicella-
related complications (VRCs); Bavaria, 2005–2011
All children hospitalized
with varicella
(VRH)
Hospitalized varicella
patients with speciﬁc
complications (VRC)
Hospitalized varicella
patients without
speciﬁc complications
p valuea
N = 1263 N = 954 N = 309
n (%) or median (IQR) n (%) or median (IQR) n (%) or median (IQR)
Demographic data
Gender male 689 (54.6) 518 (54.3) 171 (55.3) 0.793
Age (years) 3.0 (1.0–5.0) 3.0 (1.0–5.0) 4.0 (1.0–5.5) 0.111
Age groups
0–4 years 856 (67.8) 661 (69.3) 195 (63.1) 0.114
5–9 years 331 (26.2) 240 (25.2) 91 (29.4)
10–16 years 76 (6.0) 53 (5.6) 23 (7.4)
Underlying chronic conditionsb
At least one underlying
medical condition
270 (21.4) 169 (17.7) 101 (32.7) \0.001***
Malignancies/hematologic
disorder/disorders of the
immune system
113 (8.9) 64 (6.7) 49 (15.9) \0.001***
Neurologic disorder 48 (3.8) 30 (3.1) 18 (5.8) 0.039*
Failure to thrive/developmental
disorder/preterm birth
34 (2.7) 25 (2.6) 9 (2.9) 0.840
Cardiovascular/pulmonary
disorders
32 (2.5) 26 (2.7) 6 (1.9) 0.537
Metabolic disorders 28 (2.2) 20 (2.1) 8 (2.6) 0.657
Ear/nose/throat/eye 20 (1.6) 17 (1.8) 3 (1.0) 0.436
Congenital malformation 10 (0.8) 8 (0.8) 2 (0.6) 1.000
Genitourinary disorders 8 (0.6) 5 (0.5) 3 (1.0) 0.413
Syndromal disease 7 (0.6) 5 (0.5) 2 (0.6) 0.682
Other comorbidity 63 (5.0) 39 (4.1) 24 (7.8) 0.015*
Hospital stay and outcome
Varicella infection/complication
main reason for hospital
admission (= main
diagnostic code)
1082 (85.7) 884 (92.7) 198 (64.1) \0.001***
Duration of hospital stay
(days)
3.0 (2.0–6.0) 4.0 (2.0–6.0) 2.0 (1.7–4.0) \0.001***
Complex intensive care
treatment
5 (0.4) 5 (0.5) 0 (0.0) 0.343
Fatalities 2 (0.2) 2 (0.2) 0 (0.0) 1.000
***Signiﬁcant at 0.1% level; **signiﬁcant at 1% level; *signiﬁcant at 5% level
a p value for comparison of children hospitalized with varicella with and without a speciﬁc complication; Pearson’s Chi2 or Fisher’s
exact test as appropriate and Mann-Whitney U test for continuous variables
b Multiple nominations possible
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Table 2 Varicella-associated complications (VRC) in 954 (76%) of 1263 hospitalized children; Bavaria, 2005–2011
Complication category Number of diagnoses
N (% of 1263 patients)
Number of patients
N (% of 1263 patients)
Gastrointestinal complication 433 (34.3) 339 (26.8)
Dehydration 227 (18.0)
Enteritis/gastroenteritis 140 (11.1)
Constipation 17 (1.3)
Other diagnoses 49 (3.9)
Neurologic 271 (21.5) 228 (18.1)
Febrile convulsion 83 (6.6)
Encephalitis/meningitis 67 (5.3)
Syncope 30 (2.4)
Cerebral convulsion 29 (2.3)
Facial nerve palsy 8 (0.6)
Cerebral vasculitis/infarction 4 (0.3)
Other diagnoses 50 (4.0)
Skin 217 (17.2) 178 (14.1)
Dermatitis/eczema/skin eruption 64 (5.1)
Phlegmon 36 (2.9)
Abscess 35 (2.8)
Skin complication due to speciﬁc co-infecting pathogen 21 (1.7)
Impetigo 16 (1.3)
Urticaria/erythema 15 (1.2)
Other diagnoses 30 (2.4)
Upper respiratory tract (URT), ear, nose and throat
(ENT), eye
232 (18.4) 190 (15.0)
Otitis 51 (4.0)
Conjunctivitis/other affection of conjunctiva 41 (3.2)
Acute URT infection, unspeciﬁed 40 (3.2)
Tonsillitis 35 (2.8)
Laryngitis/tracheitis/laryng. spasm 21 (1.7)
Other diagnoses 44 (33.5)
Lower respiratory tract (LRT) 197 (15.6) 160 (12.7)
Pneumonia 78 (6.2)
Bronchitis 64 (5.1)
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(0.6%) osteomyelitis, 5 (0.4%) systemic inflam-
matory response syndrome (SIRS), and 2 (0.2%)
necrotizing fasciitis. In children with sepsis,
seven were diagnosed with co-infecting Strepto-
coccus species (including four with Streptococcus
group A and two with S. pneumoniae) and four
with Staphylococcus species (including three
with S. aureus). Varicella-specific hematologic
complications occurred in 44 (3.5%) children.
Coagulation disorders and related sequelae were
reported in 21 (1.7%) children and reactive
arthritis in 9 (0.7%). The category ‘other com-
plications’ included feeding problems (172,
13.6%) and kidney and urinary tract complica-
tions (27, 2.1%) as the most frequent.
Annual Rates of Varicella-Related
Complications (VRCs)
During the first year of observation (2005), on
average 6.7 [95% confidence interval (CI):
5.1–8.3] patients with any specific VRC were
recorded per participating hospital. Supple-
mentary Table 1 provides information on the
number of patients with varicella-related hos-
pitalizations and complication categories
Table 2 continued
Complication category Number of
diagnosesN (% of 1263
patients)
Number of
patientsN (% of 1263
patients)
Respiratory failure 23 (1.8)
Pleural effusion/pyothorax 22 (1.7)
Other diagnoses 10 (0.8)
Hematologic complications 57 (4.5) 44 (3.5)
Thrombocytopenia 26 (2.1)
Anemia 15 (1.2)
Other diagnoses 16 (1.3)
Systemic bacterial 35 (2.8) 26 (2.1)
Sepsis 18 (1.4)
Osteomyelitis 8 (0.6)
SIRS 5 (0.4)
Necrotizing fasciitis 2 (0.2)
Other diagnoses 2 (0.2)
Coagulation and sequelae 22 (1.7) 21 (1.7)
Reactive arthritis 9 (0.7) 9 (0.7)
Other complications 312 (24.3) 258 (20.4)
Feeding problems 172 (13.6)
Kidney and urinary tract 27 (2.1)
Cardiac complications 21 (1.7)
Other diagnoses 92 (7.3)
Multiple nominations per patient possible
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including the respective rates per hospital and
year with confidence intervals. In 2006, the
highest average number of patients with VRC
was recorded (8.6; 95% CI: 6.7–10.4). During
the following years, average numbers of VRC
patients decreased continuously, from 8.0 (95%
CI: 6.2–9.7) in 2007 to 5.2 (95% CI: 3.9–6.4) in
2008, 3.0 (95% CI: 2.1–3.8) in 2009, 2.5 (95%
CI: 1.5–3.6) in 2010 to 1.5 (95% CI: 0.8–2.3) in
2011. Overall, VRCs declined significantly by
76.9% (p = 0.006) from 2005 to 2011, with the
highest reduction of average cases per hospital
and year in children aged\5 years by 89.7%
from 5.3 (95% CI: 4.0–6.6) in 2005 to 0.5 (95%
CI: 0.1–0.9; p = 0.001) in 2011. VRCs in chil-
dren aged 5–9 years were reduced by 45.1%
from 1.2 (95% CI: 0.7–1.8) in 2005 to 0.7 (95%
CI: 0.0–2.0; p = 0.109). Only few patients aged
10–16 years were reported each year, with
average patient numbers of 0.1 (95% CI:
0.0–0.3) in 2005 and 0.3 (95% CI: 0.1–0.5;
p = 0.923) in 2011.
The annual rates for the different types of
VRC per hospital and per year are presented in
Fig. 1. All the main VRC categories decreased
significantly during the 2005 to 2011 observa-
tion period. Gastrointestinal complications
decreased by 78.0% from an average patient
number per hospital of 2.1 (95% CI: 1.4–2.8; 60
patients per 29 hospitals) to 0.5 (95% CI:
0.2–0.7; 10 patients per 22 hospitals)
(p = 0.026), neurologic complications by 64.5%
from 1.8 (95% CI: 1.2–2.4; 52 patients per 29
hospitals) to 0.6 (95% CI: 0.3–1.0; 14 patients
per 22 hospitals) (p\ 0.001), and skin compli-
cations by 81.2% from 1.4 (95% CI: 0.9–2.0; 42
patients per 29 hospitals) to 0.3 (95% CI
0.0–0.6; 6 patients per 22 hospitals) (p = 0.006).
Complications of the upper respiratory tract
decreased by 96.8% from 1.4 (95% CI: 0.9–2.0;
41 patients per 29 hospitals) to 0.0 (95% CI:
0.0–0.1; 1 patient per 22 hospitals) (p = 0.006)
and of the lower respiratory tract by 90.1% from
1.4 (95% CI: 0.9–1.8; 40 patients per 29 hospi-
tals) to 0.1 (95% CI: 0.0–0.4; 3 patients per 22
hospitals) (p = 0.003). The category ‘other
complications’ decreased by 85.7% from 1.3
(95% CI 0.7–1.8; 37 patients per 29 hospitals) to
0.2 (95% CI 0.0–0.4; 4 patients per 22 hospitals)
(p = 0.050). Hematologic and systemic bacterial
complications, coagulation/sequelae, and reac-
tive arthritis also showed lower complication
rates per hospital in 2011 compared with 2005,
but the numbers were too low for formal trend
analyses. Despite the overall decreasing trend
from 2005 to 2011, a conspicuously higher
Fig. 1 Change in the rate of varicella-related complica-
tions (VRCs) in 954 children in 22–29 participating
hospitals from 2005 to 2011; average numbers per
reporting hospital are provided per year. Multiple
nominations of a patient in different VRC categories
were possible. Patients with more than one diagnosis
within a VRC category were listed only once per category
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average number of patients per hospital was
observed in 2006 and 2007 for the categories
‘gastrointestinal complications’ and ‘other
complications’ (mainly feeding problems)
compared with all other years.
Varicella-Related Complications
in Immunocompromised Children
A subgroup of 93 (7.4%) of the 1263 children
with VRH was classified as immunocompro-
mised (Table 3). They were older at hospital
admission compared with 1170 immunocom-
petent children (median age 4 years, IQR:
2.0–6.0 vs. 3 years, IQR: 1.0–5.0; p = 0.006).
Varicella infection was less often the primary
diagnosis for hospital admission than in
immunocompetent children (54.8% vs. to
88.1%, p\0.001), and their median hospital
stay duration was 2 days longer (5 days, IQR:
3.5–9.0 vs. 3 days, IQR: 2.0–6.0; p\ 0.001). One
immunocompromised child died (Supplemen-
tary Table 2). The proportion of immunocom-
promised children with a specific VRC was
lower than in immunocompetent children
(51.6% vs. 77.4%, p\0.001).
Regarding specific VRCs, immunocompro-
mised children were significantly more fre-
quently reported to have hematologic
complications (20.4% vs. 2.1%, p\ 0.001), sys-
temic bacterial infections (6.5% vs. 1.7%,
p = 0.009), and coagulation disorders and rela-
ted sequelae (5.4% vs. 1.4%, p = 0.015) than
immunocompetent children (Table 4). In con-
trast, the proportion of gastrointestinal com-
plications was lower in immunocompromised
Table 3 Characteristics of 1263 children with varicella-related hospitalization (VRH) by immune status (Bavaria,
2005–2011)
Immunocompromised
children
Immunocompetent
children
p valuea
N = 93 N = 1170
n (%) or median (IQR) n (%) or median
(IQR)
Demographic data
Gender male 44 (47.3) 645 (55.1) 0.089
Age (years) 4.0 (2.0–6.0) 3.0 (1.0–5.0) 0.006**
Age groups
0–4 years 58 (62.4) 798 (68.2) 0.493
5–9 years 29 (31.2) 302 (25.8)
10–16 years 6 (6.5) 70 (6.0)
Hospital stay and outcome
With varicella-related complication 48 (51.6) 906 (77.4) \0.001***
Varicella infection/complication main reason for
hospital admission
51 (54.8) 1031 (88.1) \ 0.001***
Duration of hospital stay (days) 5.0 (3.5-9.0) 3.0 (2.0–6.0) \0.001***
Complex intensive care treatment 0 (0.0) 5 (0.4) 0.682
Fatalities 1 (1.1) 1 (0.1) 0.142
***Signiﬁcant at 0.1% level, **signiﬁcant at 1% level, *signiﬁcant at 5% level
a p value for comparison of children hospitalized with varicella with and without a speciﬁc complication; Pearson’s Chi2 or
Fisher’s exact test as appropriate and Mann-Whitney U test for continuous variables
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children (16.1% vs. 27.7%, p = 0.015) as well as
infections of the URT (5.4% vs. 15.8%,
p = 0.004) and neurologic complications (4.3%
vs. 19.1%, p\ 0.001).
The average number of immunocompro-
mised children with VRC decreased by 86.8%
from 0.3 to 0.4 per hospital and year in
2005–2008 to 0.1–0.05 in 2009–2011.
DISCUSSION
The ICD-10 surveillance in Bavarian hospitals
conducted from 2005 to 2011 included the
majority of the Bavarian pediatric clinics (an-
nually 61–78%). Clinical data were available for
1263 children with VRH, including 954 (75.5%)
children with specific VRC. This proportion of
children with VRC was similar to other studies
in European countries [20–24]. Descriptions of
specific VRC types in hospitalized children are
available from many countries, but were often
limited by the monocentric design and low
patient numbers, whereas our multicenter study
provided solid data from 22 to 29 pediatric
hospitals. Furthermore, it is the first study to
describe a relevant impact of UVV simultane-
ously for the various types of VRC.
The incidence of the various types of VRC
varies widely among studies from different
countries. This is probably due to divergence in
sociodemographic aspects and health care sys-
tems [25] as well as differences regarding data
sources, data collection methodology, diverging
definitions of diagnoses allocated to specific
VRC categories, presence of UVV programs, and
pre-vaccination [1, 20, 22, 24, 26–29] or post-
vaccination [19, 30–32] periods observed. In
Germany, the present study from the post-vac-
cination period showed lower proportions of
neurologic (18% vs. 25%) [16] and skin com-
plications (14% vs. 23%) but higher proportions
of gastrointestinal complications (27% vs. 15%)
compared with the pre-vaccination period [1].
Table 4 Varicella-related complications (VRCs) in immunocompromised and immunocompetent children hospitalized in
Bavaria between January 2005 and December 2011
VRC in immunocompromised
patients
VRC in immunocompetent
patients
p valuea
N = 93 N = 1170
n (%) n (%)
At least one complication 48 (51.6) 906 (77.4) \0.001***
Gastrointestinal complication 15 (16.1) 324 (27.7) 0.015*
Neurologic 4 (4.3) 224 (19.1) \0.001***
Skin 7 (7.5) 171 (14.6) 0.063
URT, ENT, eye 5 (5.4) 185 (15.8) 0.004**
LRT 7 (7.5) 153 (13.1) 0.145
Hematologic complications 19 (20.4) 25 (2.1) \0.001***
Systemic bacterial 6 (6.5) 20 (1.7) 0.009**
Coagulation and sequelae 5 (5.4) 16 (1.4) 0.015*
Reactive arthritis 1 (1.1) 8 (0.7) 0.499
Other complications 22 (23.7) 236 (20.2) 0.424
Patients could appear in more than one complication category, but only once per category
***Signiﬁcant at 0.1% level, **signiﬁcant at 1% level, *signiﬁcant at 5% level
a Two-sided p value for comparison of complications in immunocompromised and immunocompetent children hospi-
talized with varicella; Pearson’s Chi2 or Fisher’s exact test as appropriate
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Although gastrointestinal complications were
the most frequent VRCs during most study
years, they showed a conspicuous peak in 2006,
a year with an exceptionally strong rotavirus
season in Germany [33]. Hence, some of the
children with varicella might have been co-in-
fected as the varicella virus and rotavirus show a
similar seasonal peak, and both affect mainly
children\5 years of age. Nevertheless, similarly
high rates (23%) of patients with gastrointesti-
nal VRC were observed in one of the largest
studies on VRC from Canada [19]. Regarding
skin complications, our results were in the typ-
ical range of 15–25% described by a recent
meta-analysis [34]. Furthermore, rates of rare
VRC types and for single VRCs corresponded
well with other reports from other large studies.
A high impact of UVV with increasing vac-
cination coverage on VRH incidence has been
shown by a multitude of studies in various
countries [35–44], but only single studies
addressed the impact of UVV on specific types
of VRC [19, 31, 45]. Corresponding to the
decrease of VRH incidence in Bavaria following
UVV [16], during the 7-year period our study
showed a significant overall decrease of VRCs by
76.9%, with the main impact on children \
5 years of age.
During the first 3 years of observation, vac-
cination coverage in the Bavarian population
had only increased slowly because of a delay in
reimbursement regulations, and VRH remained
largely on the pre-vaccination level, with some
variation in strength between varicella seasons
[12, 14, 15]. Thus, the main impact on VRCs
was seen after 2007, with a large decrease
observed in the most frequent VRC categories,
but also evident for more rare VRC types. Upper
respiratory tract VRCs almost disappeared dur-
ing the observation period. Of note, neurologic
complications and lower respiratory tract
infections (both usually requiring longer hos-
pital stay) also showed a reduction of 64.5% and
90.1%, respectively.
A recent literature review summarized the
annual societal costs of varicella in the pre-
vaccination era at 187.5 million euros, of which
18% were direct medical costs [46]. Hospital-
izations due to (severe) varicella complications
are the main contributors to the direct medical
costs of varicella [47]. For Europe, it has been
estimated that about 18,200 to 23,500 VRHs
occur each year, the majority in children [4].
Thus, the decrease observed in both frequent
and severe VRCs due to UVV suggested a con-
siderable reduction not only of direct medical
costs but of societal costs as well.
During the 7-year observation period, we
found some decline of VRHs in immunocom-
promised children, suggesting herd protection
effects, but analyses were limited by the low
patient numbers. The analyzed data sets did not
contain information regarding possible pre-
emptive use of acyclovir. Nevertheless, about
half of the immunocompromised children with
varicella were admitted without a specific VRC.
Hence, it is likely that these VRHs were pre-
ventive measures rather than indicated because
of a severe course of varicella disease. Although
VRCs occurred less frequently, their overall
severity was higher in immunocompromised
patients, with a higher occurrence of severe
bacterial and hematologic complications. Neu-
rologic complications occurred less frequently
in immunocompromised patients, similarly as
observed in our pre-vaccination study [1]. For
the subgroup of oncologic patients, differences
in the frequencies of specific VRCs were dis-
cussed previously [18].
Two fatal cases occurred, both in children
with severe chronic conditions, one of them
explicitly attributed to a diagnosis of varicella
pneumonia. One child was aged \ 11 months
and therefore not indicated yet for varicella
vaccination. In the other child, varicella vacci-
nation was contraindicated. Children with
contraindications or newborn/infants are likely
to benefit from indirect vaccination effects in
populations with high vaccination coverage.
Limitations of this study include lack of
information on (permanent) sequelae for chil-
dren with VRC. Nevertheless, as the overall
numbers of VRC decreased, it is likely that the
rate of (permanent) sequelae attributed to vari-
cella decreased correspondingly to the increas-
ing vaccination rates. The hospital databases
did not include information on varicella vacci-
nation, and therefore we could not identify
possible varicella breakthrough cases. However,
breakthrough varicella cases usually have a
Infect Dis Ther
milder course of disease than in unvaccinated
children [35, 48] and therefore rarely result in
hospitalization. A recent literature review out-
lined that only about 0–4% of VRHs were
breakthrough varicella cases, based on results
from 12 studies in 9 countries [49]. Available
treatment data were limited and not sufficiently
detailed to evaluate treatment effects during the
course of varicella disease. Furthermore, verifi-
cation of diagnoses and coding via medical
record review was not feasible in our study,
which is a previously discussed limitation of
pseudonymized hospital discharge-based data
[1, 16, 36]. This may potentially lead to over-
estimation of specific VRCs (including children
with multiple hospital admissions) or underes-
timation (children with late-stage complica-
tions not attributed to the varicella infection
during the allocation of ICD-10 codes).
CONCLUSION
In the first 7 years following the introduction of
UVV in Germany, we observed a substantial
decline in VRC—about 76.9% overall—in both
previously healthy and immunocompromised
children of all age groups, but this was espe-
cially strong in children \ 5 years of age. The
impact affected all types of VRCs, with the
highest reductions for VRCs of the respiratory
tract.
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